Our continuous Centrifugal Microfluidics (CCM) CTC disc (CTCD) platform provides high-efficient, negative-depletion isolation of rare cells from the whole blood of a patient sample.

This unbiased isolation technology overcomes the limitation of conventional cell-based liquid biopsy which can enrich only rare cells with specific antigens or sizes.

Our platform showed its clinical utility in cancer diagnosis with circulating tumor cells(CTCs).